Chromosome translocations in multiple myeloma

Peter Leif Bergsagel, W. Michael Kuehl

Research output: Contribution to journalArticle

346 Citations (Scopus)

Abstract

Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60-65% in intramedullarly MM, 70-80% in extramedullary MM, and >90% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3′ enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.

Original languageEnglish (US)
Pages (from-to)5611-5622
Number of pages12
JournalOncogene
Volume20
Issue number40 REV. ISS. 4
DOIs
StatePublished - Sep 10 2001
Externally publishedYes

Fingerprint

Multiple Myeloma
Chromosomes
Monoclonal Gammopathy of Undetermined Significance
Plasma Cells
Oncogenes
Cyclin D3
Cell Line
Neoplasms
Plasmacytoma
Cyclin D1
Genetic Recombination
B-Lymphocytes
Bone Marrow
Phenotype
DNA
Incidence

Keywords

  • MGUS
  • Myeloma
  • Primary translocation
  • Secondary translocation

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Chromosome translocations in multiple myeloma. / Bergsagel, Peter Leif; Michael Kuehl, W.

In: Oncogene, Vol. 20, No. 40 REV. ISS. 4, 10.09.2001, p. 5611-5622.

Research output: Contribution to journalArticle

Bergsagel, PL & Michael Kuehl, W 2001, 'Chromosome translocations in multiple myeloma', Oncogene, vol. 20, no. 40 REV. ISS. 4, pp. 5611-5622. https://doi.org/10.1038/sj.onc.1204641
Bergsagel, Peter Leif ; Michael Kuehl, W. / Chromosome translocations in multiple myeloma. In: Oncogene. 2001 ; Vol. 20, No. 40 REV. ISS. 4. pp. 5611-5622.
@article{a033962b7b53443c958a2caf146765ea,
title = "Chromosome translocations in multiple myeloma",
abstract = "Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50{\%} in MGUS, 60-65{\%} in intramedullarly MM, 70-80{\%} in extramedullary MM, and >90{\%} in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3′ enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.",
keywords = "MGUS, Myeloma, Primary translocation, Secondary translocation",
author = "Bergsagel, {Peter Leif} and {Michael Kuehl}, W.",
year = "2001",
month = "9",
day = "10",
doi = "10.1038/sj.onc.1204641",
language = "English (US)",
volume = "20",
pages = "5611--5622",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "40 REV. ISS. 4",

}

TY - JOUR

T1 - Chromosome translocations in multiple myeloma

AU - Bergsagel, Peter Leif

AU - Michael Kuehl, W.

PY - 2001/9/10

Y1 - 2001/9/10

N2 - Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60-65% in intramedullarly MM, 70-80% in extramedullary MM, and >90% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3′ enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.

AB - Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60-65% in intramedullarly MM, 70-80% in extramedullary MM, and >90% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3′ enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.

KW - MGUS

KW - Myeloma

KW - Primary translocation

KW - Secondary translocation

UR - http://www.scopus.com/inward/record.url?scp=0035839841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035839841&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1204641

DO - 10.1038/sj.onc.1204641

M3 - Article

C2 - 11607813

AN - SCOPUS:0035839841

VL - 20

SP - 5611

EP - 5622

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 40 REV. ISS. 4

ER -